FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215679919> ?p ?o ?g. }

• W3215679919 endingPage "iii371" @default.
• W3215679919 startingPage "iii371" @default.
• W3215679919 abstract "Abstract BACKGROUND Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. It is now known that the majority of PLGG have activation of the MAPK/ERK pathway. We hypothesize that we will observe responses in recurrent/refractory PLGG treated with trametinib. METHODS This is a multicenter phase II including three progressing/refractory PLGG groups: NF1 patients, KIAA1549-BRAF fusion patients and patients with other activation of the MAPK/ERK pathway (excluding V600E). Patients will receive daily oral trametinib for a total of 18 cycles of 28 days. A total of 104 patients will be enrolled in seven Canadian centers. Secondary objectives include the assessment of progression-free survival, tolerability of trametinib, serum levels of trametinib and evaluation of quality of life during treatment. RESULTS As of January 7 2020, 28 patients have been enrolled (NF1: 6 patients, KIAA1549-BRAF fusion: 17, other: 5 including 3 patients FGFR1 alteration). Median age is 8.5 years (range 2.5–25.4 years). Median follow-up is currently 4.6 months (range 0.16–14.7 months). Twenty patients are currently evaluable. Best response includes: 1 complete response (5%), 3 partial response (15%), 4 minor response (20%), 8 stable disease (40%), 4 progressive disease (20%). 8 patients (28,5%) discontinued treatment: 4 for progressive disease, 3 adverse event (alanine aminotransferase increase), 1 withdrew. CONCLUSION Trametinib is potential effective targeted therapy for patients with recurrent/refractory PLGG. Overall treatment is well tolerated. This ongoing trial will continue to gather data on response rate, duration of response and safety of trametinib for PLGG." @default.
• W3215679919 created "2021-12-06" @default.
• W3215679919 creator A5010939758 @default.
• W3215679919 creator A5012407631 @default.
• W3215679919 creator A5023634414 @default.
• W3215679919 creator A5026291256 @default.
• W3215679919 creator A5031468557 @default.
• W3215679919 creator A5041812677 @default.
• W3215679919 creator A5046177638 @default.
• W3215679919 creator A5049032455 @default.
• W3215679919 creator A5052269630 @default.
• W3215679919 creator A5055427963 @default.
• W3215679919 creator A5056194952 @default.
• W3215679919 creator A5063974521 @default.
• W3215679919 creator A5068257880 @default.
• W3215679919 creator A5068881416 @default.
• W3215679919 creator A5069822100 @default.
• W3215679919 creator A5080379495 @default.
• W3215679919 creator A5082885008 @default.
• W3215679919 creator A5089057590 @default.
• W3215679919 creator A5091013379 @default.
• W3215679919 date "2020-12-01" @default.
• W3215679919 modified "2023-10-06" @default.
• W3215679919 title "LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01" @default.
• W3215679919 doi "https://doi.org/10.1093/neuonc/noaa222.407" @default.
• W3215679919 hasPublicationYear "2020" @default.
• W3215679919 type Work @default.
• W3215679919 sameAs 3215679919 @default.
• W3215679919 citedByCount "1" @default.
• W3215679919 countsByYear W32156799192021 @default.
• W3215679919 crossrefType "journal-article" @default.
• W3215679919 hasAuthorship W3215679919A5010939758 @default.
• W3215679919 hasAuthorship W3215679919A5012407631 @default.
• W3215679919 hasAuthorship W3215679919A5023634414 @default.
• W3215679919 hasAuthorship W3215679919A5026291256 @default.
• W3215679919 hasAuthorship W3215679919A5031468557 @default.
• W3215679919 hasAuthorship W3215679919A5041812677 @default.
• W3215679919 hasAuthorship W3215679919A5046177638 @default.
• W3215679919 hasAuthorship W3215679919A5049032455 @default.
• W3215679919 hasAuthorship W3215679919A5052269630 @default.
• W3215679919 hasAuthorship W3215679919A5055427963 @default.
• W3215679919 hasAuthorship W3215679919A5056194952 @default.
• W3215679919 hasAuthorship W3215679919A5063974521 @default.
• W3215679919 hasAuthorship W3215679919A5068257880 @default.
• W3215679919 hasAuthorship W3215679919A5068881416 @default.
• W3215679919 hasAuthorship W3215679919A5069822100 @default.
• W3215679919 hasAuthorship W3215679919A5080379495 @default.
• W3215679919 hasAuthorship W3215679919A5082885008 @default.
• W3215679919 hasAuthorship W3215679919A5089057590 @default.
• W3215679919 hasAuthorship W3215679919A5091013379 @default.
• W3215679919 hasBestOaLocation W32156799191 @default.
• W3215679919 hasConcept C126322002 @default.
• W3215679919 hasConcept C141071460 @default.
• W3215679919 hasConcept C142424586 @default.
• W3215679919 hasConcept C143998085 @default.
• W3215679919 hasConcept C184235292 @default.
• W3215679919 hasConcept C197934379 @default.
• W3215679919 hasConcept C2778375690 @default.
• W3215679919 hasConcept C2778472372 @default.
• W3215679919 hasConcept C57074206 @default.
• W3215679919 hasConcept C71924100 @default.
• W3215679919 hasConcept C86803240 @default.
• W3215679919 hasConcept C87355193 @default.
• W3215679919 hasConcept C90924648 @default.
• W3215679919 hasConcept C95444343 @default.
• W3215679919 hasConceptScore W3215679919C126322002 @default.
• W3215679919 hasConceptScore W3215679919C141071460 @default.
• W3215679919 hasConceptScore W3215679919C142424586 @default.
• W3215679919 hasConceptScore W3215679919C143998085 @default.
• W3215679919 hasConceptScore W3215679919C184235292 @default.
• W3215679919 hasConceptScore W3215679919C197934379 @default.
• W3215679919 hasConceptScore W3215679919C2778375690 @default.
• W3215679919 hasConceptScore W3215679919C2778472372 @default.
• W3215679919 hasConceptScore W3215679919C57074206 @default.
• W3215679919 hasConceptScore W3215679919C71924100 @default.
• W3215679919 hasConceptScore W3215679919C86803240 @default.
• W3215679919 hasConceptScore W3215679919C87355193 @default.
• W3215679919 hasConceptScore W3215679919C90924648 @default.
• W3215679919 hasConceptScore W3215679919C95444343 @default.
• W3215679919 hasIssue "Supplement_3" @default.
• W3215679919 hasLocation W32156799191 @default.
• W3215679919 hasLocation W32156799192 @default.
• W3215679919 hasOpenAccess W3215679919 @default.
• W3215679919 hasPrimaryLocation W32156799191 @default.
• W3215679919 hasRelatedWork W1967853306 @default.
• W3215679919 hasRelatedWork W2109512293 @default.
• W3215679919 hasRelatedWork W2351796763 @default.
• W3215679919 hasRelatedWork W2378369323 @default.
• W3215679919 hasRelatedWork W2464877492 @default.
• W3215679919 hasRelatedWork W2492626689 @default.
• W3215679919 hasRelatedWork W2528057197 @default.
• W3215679919 hasRelatedWork W2793900558 @default.
• W3215679919 hasRelatedWork W4318426573 @default.
• W3215679919 hasRelatedWork W4376129482 @default.
• W3215679919 hasVolume "22" @default.
• W3215679919 isParatext "false" @default.
• W3215679919 isRetracted "false" @default.
• W3215679919 magId "3215679919" @default.

• next